Kontekst branży
Grifols SA [GRFS]
Ostatnia aktualizacja 24 Jun 2026 @ 16:00 (Exchange is closed)
Ostatnia: $7.22
0.56%
-4.29 (↑)
GaG Algo Score™
v1.0
Krótki
-4.29 (↑)
Średni
-5.74 (↑)
Długi
-5.42 (↑)
Linia
Dane pivot
Statystyki pivot
| Metryka | Średnia | Mediana | Odch. std. |
|---|---|---|---|
| Zysk % | 20.11% | 15.81% | 12.89% |
| Strata % | -16.76% | -12.80% | 10.22% |
| Czas trwania | 22.2d | 18d | 17.8d |
| Łącznie znalezionych pivotów | 41 |
| Odcinki zysk/strata | 40 (20 Zysk / 20 Strata) |
| Ostatni pivot | Top @ $8.19 dnia 2026-05-20 |
| Zmiana od ostatniego pivotu | $-0.97 (-11.84%) |
Prognoza następnego pivotu Ostatnia: $7.22
| Przewidywany następny typ | Bottom |
| Prognozowana cena (średnia) | $6.82 |
| Prognozowana cena (mediana) | $7.14 |
| Prognozowany zakres ceny (~68%) | $5.98 - $7.65 |
| Zmiana do średniego celu | $-0.40 (-5.58%) |
| Prognozowana data (średnia) | 2026-06-11 |
| Prognozowany zakres dat (~68%) | 2026-05-24 - 2026-06-29 |
| Podstawa | Based on 20 historical losses (Avg: -16.76%, Median: -12.80%, StdDev of Abs: 10.22%) and duration (Avg: 22.2 days, StdDev: 17.8 days) |
| Uwaga | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Modest rise for Grifols SA.
Grifols SA (GRFS) stock price climbed on Wednesday after the stock rose $0.0400 (0.56%) from the previous session on normal volume. The stock held up slightly better than the falling NASDAQ (-0.43% down). A total of 805 341 stocks were traded yesterday, valued at $5.81M, 148 993 shares more than the previous day (656 348 shares traded). This is above the average volume for the stock at 670 190 shares traded per day.
Grifols SA signals
There is no conclusive signals given from RSI. The price is below both moving averages, and the short-term average is below the long-term average, confirming a sustained down-trend. Strong Bearish Consensus: A significant wave of negative pressure is evident across all time horizons. Technical indicators are decisively bearish in the short-term (18/30, net -50%), medium-term (18/30, net -50%), and long-term (18/30, net -50%), signaling a robust and sustained downtrend.
Grifols SA Support & Resistance Levels
The stock is trading above the closest support level at $7.20. approximately $0.0200 (0.28%) away. This suggests it is currently acting as a floor, consolidating near support.The sup dis das support s17.2 -
Grifols SA Evaluation
- Krótki wynik: -4.29
- Średni wynik: -5.74
- Długi wynik: -5.42
Mapa relacji
Obraz korelacji
Kontekst zdarzeń
Wolumen i dywidendy
Długa korel. wolumenu
-0.11
Krótka korel. wolumenu
0.20
Positioning pressure
Short interest pressure
Short interest
0.70%
Of outstanding shares
Short float
0.70%
Of tradable float
Days to cover
9.83
Short interest divided by average volume
Squeeze probability
0.80%
-1.34% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Income profile
Dividend profile
Ostatnia dywidenda
$0.176
2025-08-12
Następna dywidenda
$0
N/A
Avg. yearly yield
0.62%
Annually
Total paid
$2.77
17 payments
Sustainability
0
low (50.00%)
Growth potential
0
No dividend expected
Direction
0
Score based on dividend trend and payout behavior.
Yearly history
| Year | Dividend | Yield |
|---|---|---|
| - | $0 | 0.00% |
| - | $0.176 | 2.33% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0.360 | 1.90% |
Recent payments
| Date | Dividend | Payment |
|---|---|---|
| 2025-08-12 | $0.176 | 2025-08-20 |
| 2021-06-03 | $0.360 | 2021-06-14 |
| 2020-10-30 | $0.143 | 2020-11-09 |
| 2019-12-02 | $0.170 | 2019-12-11 |
| 2019-06-07 | $0.132 | 2019-06-18 |
Earnings quality
Earnings history
Reported quarters
10
EPS beats
1
EPS misses
9
Avg. surprise
-41.79%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| ~2025 Q3? | 2025-11-05 | - | - | - | - |
| ~2025 Q2? | 2025-07-28 | - | $0.222 | - | - |
| ~2025 Q1? | 2025-05-12 | $0.100 | $0.140 | -28.57% | 1.99B |
| ~2024 Q4? | 2025-03-06 | $0.260 | $0.130 | 100.00% | 2.05B |
| ~2024 Q3? | 2024-11-07 | $0.160 | $0.220 | -27.27% | 1.97B |
| ~2024 Q2? | 2024-07-30 | $0.0200 | $0.230 | -91.30% | 1.95B |
| ~2024 Q1? | 2024-05-14 | $0.0700 | $0.150 | -53.33% | 1.76B |
| ~2023 Q4? | 2024-03-05 | $0.140 | $0.220 | -36.36% | 1.95B |
News flow
Latest company news
Market coverage
globenewswire.com Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S. Jun 15, 2026 seekingalpha.com Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst Jun 4, 2026 seekingalpha.com Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript May 9, 2026 defenseworld.net Aldeyra Therapeutics (NASDAQ:ALDX) and Grifols (NASDAQ:GRFS) Head to Head Comparison Apr 13, 2026Company releases
Company context
Company profile
Giełda:
NASDAQ
Sektor:
Healthcare
Branża:
Drug Manufacturers General
Currency
USD
Grifols SA a company founded in 1940 and headquartered in Barcelona Spain specializes in the development manufacture and distribution of therapeutic products with a primary focus on those derived from human plasma Its operations are organized into several divisions The Bioscience division is dedicated to researching producing and marketing plasmaderived medicines such as immunoglobulins alpha1 antitrypsin albumin and clotting factors along with other innovative treatments for chronic rare prevalent and lifethreatening conditions The Hospital division provides nonbiological pharmaceuticals medical supplies clinical nutrition solutions intravenous therapies and medical devices The Diagnostic division develops manufactures and commercializes diagnostic products that span the entire healthcare continuum from prevention and screening to diagnosis prognosis and monitoring of diseases and treatments catering to professional healthcare providers The Bio Supplies division offers essential biological materials for lifescience research clinical trials and the manufacturing of pharmaceutical and diagnostic products These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia immune deficiencies and infectious diseases Grifols serves a wide array of clients including public and private healthcare organizations wholesalers distributors group purchasing organizations blood banks hospitals and national health systems The company also maintains a technology collaboration agreement with Mondragon
Navigation